Natixis Advisors LLC Sells 2,126 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Natixis Advisors LLC lessened its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 1.7% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 119,434 shares of the biopharmaceutical company’s stock after selling 2,126 shares during the quarter. Natixis Advisors LLC owned about 0.09% of Halozyme Therapeutics worth $5,710,000 at the end of the most recent quarter.

A number of other large investors have also recently modified their holdings of HALO. Raymond James Financial Inc. bought a new stake in Halozyme Therapeutics in the 4th quarter worth approximately $21,838,000. Janney Montgomery Scott LLC lifted its position in Halozyme Therapeutics by 698.8% in the 4th quarter. Janney Montgomery Scott LLC now owns 287,731 shares of the biopharmaceutical company’s stock worth $13,756,000 after buying an additional 251,711 shares during the last quarter. Victory Capital Management Inc. lifted its position in Halozyme Therapeutics by 60.0% in the 4th quarter. Victory Capital Management Inc. now owns 650,751 shares of the biopharmaceutical company’s stock worth $31,112,000 after buying an additional 243,940 shares during the last quarter. Boston Trust Walden Corp lifted its position in Halozyme Therapeutics by 28.0% in the 4th quarter. Boston Trust Walden Corp now owns 874,081 shares of the biopharmaceutical company’s stock worth $41,790,000 after buying an additional 191,465 shares during the last quarter. Finally, Hantz Financial Services Inc. bought a new stake in Halozyme Therapeutics in the 3rd quarter worth approximately $9,260,000. Institutional investors own 97.79% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on the company. Benchmark restated a “buy” rating and issued a $75.00 target price on shares of Halozyme Therapeutics in a research report on Thursday, February 20th. Wells Fargo & Company decreased their price target on Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating on the stock in a research note on Monday, January 13th. Piper Sandler lifted their price target on Halozyme Therapeutics from $52.00 to $53.00 and gave the stock a “neutral” rating in a research note on Friday, January 10th. Finally, HC Wainwright reaffirmed a “buy” rating on shares of Halozyme Therapeutics in a research note on Thursday, March 6th. Four research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to MarketBeat, Halozyme Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $62.78.

Insider Activity

In related news, Director Jeffrey William Henderson sold 5,000 shares of the company’s stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $58.69, for a total value of $293,450.00. Following the sale, the director now directly owns 33,611 shares of the company’s stock, valued at $1,972,629.59. This represents a 12.95 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, SVP Michael J. Labarre sold 1,697 shares of the company’s stock in a transaction on Thursday, February 27th. The stock was sold at an average price of $58.28, for a total value of $98,901.16. Following the completion of the sale, the senior vice president now directly owns 173,756 shares in the company, valued at approximately $10,126,499.68. The trade was a 0.97 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 31,697 shares of company stock valued at $1,754,451. Company insiders own 2.40% of the company’s stock.

Halozyme Therapeutics Price Performance

HALO opened at $65.16 on Friday. The company has a debt-to-equity ratio of 4.14, a quick ratio of 9.15 and a current ratio of 7.80. Halozyme Therapeutics, Inc. has a 52-week low of $37.73 and a 52-week high of $65.53. The stock has a market capitalization of $8.02 billion, a PE ratio of 19.00, a price-to-earnings-growth ratio of 0.42 and a beta of 1.32. The stock’s 50 day moving average price is $58.20 and its 200-day moving average price is $54.76.

Halozyme Therapeutics (NASDAQ:HALO) last posted its earnings results on Tuesday, February 18th. The biopharmaceutical company reported $1.19 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.17 by $0.02. Halozyme Therapeutics had a return on equity of 157.78% and a net margin of 43.74%. The firm had revenue of $298.01 million for the quarter, compared to analysts’ expectations of $285.74 million. On average, equities research analysts predict that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current year.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.